Lumos Diagnostics (ASX: LDX) has extended its agreement with Henry Schein Medical’s European business for the FebriDx point-of-care test.
The agreement further expands the distribution of FebriDx through Henry Schein’s Medical business to include Belgium.
FebriDx is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. It delivers results after 10 minutes from a fingerstick blood sample and can be used to help rapidly and accurately manage infectious patients in Primary Care, Urgent Care, Emergency Dept, Paediatric and other Outpatient settings.
Henry Schein is the world’s largest provider of health care solutions to office-based dental and medical practitioners, currently distributes the FebriDx test in the Netherlands, Portugal, Spain, the UK, and the US. Its medical business expanded into the Belgium market in 2023, specifically serving general practitioners and midwives.
“Our team is dedicated to providing innovative, integrated health care products, together with our supplier partners, that customers can rely on,” said Alain Nijsing, General Manager of Henry Schein Medical Netherlands and Belgium.
“By partnering with Lumos to now offer FebriDx in Belgium, we can help health care professionals around the world have access to the tools needed to continue providing quality care.”
According to the Belgian Federal Public Service (FPS) Health, Food Chain, Safety and Environment, antimicrobial resistance is one of the greatest threats to public health today and in the future.
Recently, an independent study by UK researchers, published in the Journal of Antimicrobial Chemotherapy, has shown that using FebriDx led to a reduction in antibiotic prescribing intentions for patients with lower respiratory tract infections. In primary care, lower respiratory tract infections are a common reason for antibiotic prescriptions.
“We are pleased to continue to partner with Henry Schein in various countries to provide access to FebriDx and help address the global challenge of antimicrobial resistance,” said Doug Ward, CEO of Lumos Diagnostics.
“By providing clinicians with rapid and accurate information about the nature of a patient's infection, FebriDx can help health care professionals make more informed decisions about antibiotic use, ultimately benefiting both individual patients and public health.”
